The Hemodynamic Response to Prolonged Dobutamine Infusion

H

Hadassah Medical Center

Status and phase

Unknown
Phase 4

Conditions

Healthy
Heart Failure

Treatments

Drug: 3 hours intravenous dobutamine

Study type

Interventional

Funder types

Other

Identifiers

NCT01042873
0355-09-HMO-CTIL
0355-09-HMO (Other Identifier)

Details and patient eligibility

About

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo. Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

healthy subjects

Exclusion criteria

  • consumption of any medications during the 2 weeks prior to the study
  • history of chest pain or tachycardia

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

Intravenous dobutamine
Other group
Description:
3 hours infusion of dobutamine
Treatment:
Drug: 3 hours intravenous dobutamine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems